ArticleCureus2026
Two Cases of Papillary Thyroid Carcinoma With QTc Prolongation During Selpercatinib Administration: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selpercatinib (SEL) is a selective RET (rearranged during transfection) inhibitor that has a good safety profile and potent antitumor effects against RET mutation-positive medullary thyroid carcinoma and RET fusion gene-positive thyroid carcinoma, as demonstrated by the LIBRETTO-001 trial. Its major adverse effects include hypertension, hepatic dysfunction, QTc prolongation, hypersensitivity, and interstitial lung disease. In two patients who received the drug at the study center, SEL demonstrated strong antitumor efficacy but induced QTc prolongation, necessitating a dose reduction or treatment interruption. The first case involved a 76-year-old female patient with a history of surgery for papillary thyroid carcinoma who had been referred to our department in 2024 due to difficulty with walking caused by right iliac metastases. The patient regained the ability to walk after SEL administration shrank the tumors, but due to QTc prolongation, the treatment was interrupted, and the dosage was reduced. The second case involved a 54-year-old male patient with papillary thyroid carcinoma and lung metastases who had undergone a total thyroidectomy followed by radioactive iodine therapy in 2019. Subsequently, metastases developed in the intracranial region, bones, liver, muscles, and adrenal glands, leading to the implementation of SEL therapy in September 2024. QTc prolongation occurred on day 14 of treatment. After the treatment was interrupted for one week, the dosage was reduced to 240 mg/day and has been maintained at this level since then. Following this dose adjustment, the liver metastases resolved, and the other metastases decreased in size. No progression was observed at month 14 after the start of the treatment. In the LIBRETTO-001 trial, QTc prolongation of any grade occurred in approximately 16% of patients, with Grade 3 or higher events reported in about 4%. Reports of QTc prolongation associated with SEL therapy for thyroid cancer remain limited. However, QTc prolongation occurred in both of our patients, suggesting that it may represent a clinically relevant concern in selected individuals. Appropriate dose adjustment and careful monitoring may facilitate continued treatment in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.